Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares were up 4.7% during trading on Wednesday . The company traded as high as $7.18 and last traded at $6.84, with a volume of 1,854,571 shares changing hands. The stock had previously closed at $6.53.

A number of research analysts have recently commented on RPTP shares. Wedbush reissued a “neutral” rating and set a $4.00 price objective on shares of Raptor Pharmaceutical Corp. in a report on Friday, May 6th. Zacks Investment Research raised Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Thursday, August 11th. Citigroup Inc. lowered Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and increased their price objective for the company from $6.00 to $8.00 in a report on Monday, August 8th. Finally, FBR & Co reissued a “hold” rating on shares of Raptor Pharmaceutical Corp. in a report on Sunday, June 12th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $7.21.

The stock’s 50 day moving average price is $6.05 and its 200-day moving average price is $5.03. The firm’s market cap is $593.73 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The business had revenue of $32.05 million for the quarter, compared to the consensus estimate of $28.52 million. The business’s revenue was up 37.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. On average, equities research analysts forecast that Raptor Pharmaceutical Corp. will post ($0.90) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned about 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 as of its most recent SEC filing.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.